Cagrilintide + Semaglutide — Dual Amylin & GLP-1 Receptor Research Peptide Blend

Cagrilintide + Semaglutide is a research-grade combination formulation that delivers two complementary metabolic peptides in a single lyophilized vial. It pairs Cagrilintide — a long-acting fatty acid-modified amylin analogue — with Semaglutide — a well-characterized GLP-1 receptor agonist. Researchers use this cagrilintide semaglutide research peptide to study the simultaneous activation of two distinct hormonal satiety axes and their combined effects on energy homeostasis, food intake, and metabolic regulation. Furthermore, consolidating both compounds into one formulation simplifies dosing, reduces preparation time, and supports cleaner experimental designs in dual-hormone research protocols.

Mechanism of Action

This blend activates two separate and complementary receptor systems simultaneously.

Semaglutide binds the GLP-1 receptor (GLP-1R) on pancreatic beta-cells, intestinal L-cells, and hypothalamic neurons. It drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and activates hypothalamic satiety circuits through GLP-1R/cAMP/PKA signaling. Additionally, its C-18 fatty diacid modification enables albumin binding, extending its half-life and ensuring sustained GLP-1R engagement throughout the experimental timeframe.

Cagrilintide concurrently activates amylin receptors (AMY1–3) and calcitonin receptors in the brainstem — specifically the area postrema and nucleus tractus solitarius. These receptors mediate a distinct satiety signal that operates independently of GLP-1R pathways. Furthermore, amylin receptor activation suppresses post-prandial glucagon secretion and slows gastric emptying through a separate mechanistic route.

Consequently, the combination engages both the hypothalamic GLP-1R satiety axis and the brainstem amylinergic satiety axis simultaneously. This dual-pathway activation produces a more comprehensive satiety signal profile than either compound achieves alone. Therefore, researchers studying the full hormonal landscape of energy balance regulation specifically require this amylin GLP-1 dual hormone research compound.

Key Research Applications

Researchers actively use this blend across multiple specialized research domains. Specifically, it supports:

• Dual satiety pathway research — Simultaneous investigation of GLP-1R-mediated hypothalamic satiety signaling and AMY receptor-mediated brainstem satiety circuits in the same experimental system.
• Complementary receptor pharmacology — Studies examining how GLP-1R and amylin receptor co-activation interacts at the level of downstream cAMP, MAPK, and PI3K signaling cascades.
• Energy balance and food intake studies — Preclinical models investigating the combined effect of dual receptor activation on cumulative food intake, meal frequency, and energy expenditure relative to mono-therapy controls.
• Glucagon regulation research — Studies examining the additive glucagon-suppressive effects of simultaneous GLP-1R and amylin receptor activation from complementary mechanistic pathways.
• Gastric motility studies — Investigation of combined amylinergic and GLP-1R-mediated effects on gastric emptying rate and gastrointestinal transit in preclinical model systems.
• Comparative combination research — Experimental designs benchmarking dual amylin/GLP-1 receptor activation against GLP-1 mono-agonist, dual incretin agonist (GLP-1T), and triple agonist (GLP-1R) compounds to map the incremental contribution of amylin receptor co-activation.

Advantages Over Individual Compound Protocols

Researchers running dual-hormone protocols with separate Cagrilintide and Semaglutide vials face practical challenges. These include independent reconstitution, separate dosing calculations, and increased variability in combined dosing accuracy. This pre-formulated cagri sema combination peptide addresses all of these challenges directly. Both compounds share a single reconstitution step, a single vial, and a unified dosing volume. As a result, researchers achieve greater experimental consistency and reduce the risk of preparation-related variability between study subjects or replicate experiments.

Furthermore, it serves as an ideal companion product to the individual Cagrilintide (10mg) and GLP-1S Semaglutide vials available separately — enabling researchers to design flexible mono vs. combination comparison studies within the same product range.

Peptide Profile

Reconstitution Guidelines

Reconstitute with sterile bacteriostatic water. Add solvent slowly along the inner vial wall and gently swirl until the lyophilized powder fully dissolves. Do not shake or vortex. For the 10mg combination vial, researchers typically add 1–2ml of solvent to achieve a suitable working concentration. Additionally, prepare single-use aliquots before storage at 4°C to minimize repeated freeze-thaw exposure across extended experimental protocols.

Storage Conditions

Store lyophilized vials at −20°C, protected from direct light and moisture. Keep vials sealed until the point of reconstitution. Furthermore, once reconstituted, maintain at 4°C and use within 28–30 days. Avoid repeated freeze-thaw cycles to preserve the activity and receptor binding profiles of both peptide components throughout the study duration.

For research use only. Not intended for human or veterinary administration. This product is not a drug, supplement, or food product.